AAGBI Safety Guideline

Management of Severe Local Anaesthetic Toxicity

1 Recognition

Signs of severe toxicity:

- Sudden alteration in mental status, severe agitation or loss of consciousness, with or without tonic-clonic convulsions
- Cardiovascular collapse: sinus bradycardia, conduction blocks, asystole and ventricular tachyarrhythmias may all occur
- Local anaesthetic (LA) toxicity may occur some time after an initial injection

2 Immediate management

- Stop injecting the LA
- Call for help
- Maintain the airway and, if necessary, secure it with a tracheal tube
- Give 100% oxygen and ensure adequate lung ventilation (hyperventilation may help by increasing plasma pH in the presence of metabolic acidosis)
- Confirm or establish intravenous access
- Control seizures: give a benzodiazepine, thiopental or propofol in small incremental doses
- Assess cardiovascular status throughout
- Consider drawing blood for analysis, but do not delay definitive treatment to do this

3 Treatment

IN CIRCULATORY ARREST

- Start cardiopulmonary resuscitation (CPR) using standard protocols
- Manage arrhythmias using the same protocols, recognising that arrhythmias may be very refractory to treatment
- Consider the use of cardiopulmonary bypass if available

GIVE INTRAVENOUS LIPID EMULSION
(following the regimen overleaf)

- Continue CPR throughout treatment with lipid emulsion
- Recovery from LA-induced cardiac arrest may take >1 h
- Propofol is not a suitable substitute for lipid emulsion
- Lidocaine should not be used as an anti-arrhythmic therapy

WITHOUT CIRCULATORY ARREST
Use conventional therapies to treat:

- hypotension,
- bradycardia,
- tachyarrhythmia

CONSIDER INTRAVENOUS LIPID EMULSION
(following the regimen overleaf)

- Propofol is not a suitable substitute for lipid emulsion
- Lidocaine should not be used as an anti-arrhythmic therapy

4 Follow-up

- Arrange safe transfer to a clinical area with appropriate equipment and suitable staff until sustained recovery is achieved
- Exclude pancreatitis by regular clinical review, including daily amylase or lipase assays for two days
- Report cases as follows:
  - in the United Kingdom to the National Patient Safety Agency (via **www.npsa.nhs.uk**)
  - in the Republic of Ireland to the Irish Medicines Board (via **www.imb.ie**)

If Lipid has been given, please also report its use to the international registry at **www.lipidregistry.org**. Details may also be posted at **www.lipidrescue.org**

Your nearest bag of Lipid Emulsion is kept .....

IMMEDIATELY

Give an initial intravenous bolus injection of 20% lipid emulsion

1.5 ml.kg^{-1} over 1 min

AND

Start an intravenous infusion of 20% lipid emulsion at **15 ml.kg^{-1}.h^{-1}**

AFTER 5 MIN

Give **a maximum of two** repeat boluses (same dose) if:

- cardiovascular stability has not been restored **or**
- an adequate circulation deteriorates

Leave **5 min** between boluses

A maximum of **three** boluses can be given (including the initial bolus)

AND

Continue infusion at same rate, but:

Double the rate to **30 ml.kg^{-1}.h^{-1}** at any time after 5 min, if:

- cardiovascular stability has not been restored or
- an adequate circulation deteriorates

Continue infusion until stable and adequate circulation restored or maximum dose of lipid emulsion given

Do not exceed a maximum cumulative dose of 12 ml.kg^{-1}

An approximate dose regimen for a 70-kg patient would be as follows:

IMMEDIATELY

Give an initial intravenous bolus injection of 20% lipid emulsion 100 ml over 1 min

AND

Start an intravenous infusion of 20% lipid emulsion at 1000 ml.h^{-1}

AFTER 5 MIN

Give a **maximum of two** repeat boluses of 100 ml

AND

Continue infusion at same rate but **double** rate to 2000 ml.h^{-1} if indicated at any time

Do not exceed a maximum cumulative dose of 840 ml

This AAGBI Safety Guideline was produced by a Working Party that comprised:
Grant Cave, Will Harrop-Griffiths (Chair), Martyn Harvey, Tim Meek, John Picard, Tim Short and Guy Weinberg.

This Safety Guideline is endorsed by the Australian and New Zealand College of Anaesthetists (ANZCA).